The Long-Term Outcomes of Infants with Neonatal Abstinence Syndrome

Similar documents
Outcomes of Infants with Neonatal Abstinence Syndrome

Opioid Use Disorder in Pregnancy. Neonatal Abstinence Syndrome

Care of the Neonate with Prenatal Opioid Exposure. Objectives. What is Neonatal Abstinence Syndrome (NAS)/ Neonatal Opiate Withdrawal Syndrome?

Evidence-Based Update: Using Glucose Gel to Treat Neonatal Hypoglycemia

Objectives. Care of the Neonate with Prenatal Opioid Exposure. What is Neonatal Abstinence Syndrome (NAS)? Increasing Incidence of NAS 8/27/2016

IN-PATIENT PEDIATRIC REHABILITATION

SUBSTANCE EXPOSED INFANTS PRESENTED BY ECOLE J. BARROW-BROOKS M.ED & DARLENE D. OWENS MBA, LBSW, CADC, ADS

Neonatal Drug Withdrawal

Lori A. Shook, MD Division of Neonatology Kentucky Children s Hospital University of Kentucky Medical Center

Emergent Issues Affecting Early Intervention/ Early Childhood. Workforce Development for Inclusion in Early Childhood November 4, 2017 Washington, DC

Neonatal Abstinence Syndrome Epidemiology, diagnosis, management and prevention

Supplementary Appendix

Product Labeling to Communicate Benefits and Risks of Treatment for Opioid Use Disorder in Pregnant Women. Hendrée E. Jones, PhD

Gastric Residuals in Preterm Infants

Objectives. Common Drugs leading to NAS. Differential Diagnosis. Clinical Features of NAS. Assessing Neonatal Abstinence in the Newborn Nursery

Neonatal Abstinence Syndrome:

Maternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC

Relationships Relationships

Clinical Management of Neonatal Abstinence Syndrome. Tricia L. Romesberg, DNP, MSN, ARNP, CNNP

Consequences and Treatment of Opioid Abuse During Pregnancy. Katie Ellis, PharmD March 12, 2018

Neonatal Abstinence Syndrome

NAS / NOWS: Description. Disclosures: I will discuss off-label uses of medications I have no financial disclosures. Objectives

Understanding Prenatal Drug Exposure

1/26/2018 PREVENTING THE RETRAUMITIZATION OF CHILDREN FROM ADDICTED FAMILIES THE PROBLEM RISK FACTORS FOR ENDANGERMENT

A System of Care Surrounding the Drug Exposed Neonate. Disclosures. Objectives 11/17/2015. I have no financial disclosures

Presented by DCF SunCoast Region: Kyle Teague, Melissa Worthen, Christina Cuoco, Nina Romeu, Dekesha Seay

Wales Neonatal Network Guideline

Neonatal abstinence syndrome

Supersedes Date None and Management Guidelines. Originating Dept. NICU Document Owner Dir., NICU Document applies to: NCH Required Not Required

Neonatal Abstinence Syndrome (NAS)

Opioid Use in Pregnant Women and Prenatal Care. Murray F Dweck MD, FACOG Medical Director/OBGYN Florida Department of Health -Brevard

Effects of Prenatal Illicit Drug. Use on Infant and Child

Treating Women for Opioid Use Disorder during Pregnancy: Methadone and Buprenorphine as a Part of a Complete Care Approach

Common Drugs of Abuse. Tobacco/Nicotine Cannabis Alcohol Opiates Cocaine Methamphetamine. 36 weeks gestation adult

Neonatal Abstinence Syndrome (NAS)

The Impact of the Opioid Crisis on Children

EFFECTS OF PRENATAL EXPOSURES. Thomas J. Schreiner M.D. CAPT., USPHS White Earth Health Center

Development and use of the Eating, Sleeping, Consoling (ESC) Care. for opioid-exposed newborns and their families in Northern New England

MAT IN PREGNANCY KAYLA LIFE STAGE 1: ADOLESCENCE LIFE STAGE 2: EARLY ADULTHOOD. family History of addiction. addiction to oral opioids

Donor human milk may decrease severe gastrointestinal distress in infants with neonatal abstinence syndrome.

Objectives. Nothing to Disclose No Conflicts of Interest

Effective Strategies for Addressing the Needs of Substance Exposed Newborns & their Families Dixie L. Morgese, BA, CAP, ICADC.

Marijuana During Pregnancy: An Overview

NOWS The Time Caring for the Infant with Neonatal Opiate Withdrawal Syndrome

The Substance Exposed Newborn Alphabet Soup

Safe Babies Foster Parent Training Program

Science = Solutions For Substance Use Disorders and Infant Outcomes. Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse

Beyond Birth: A Comprehensive Recovery Center serving parenting women

Running head: NEONATAL ABSTINENCE SYNDROME 1

PROJECT DOVE. Improving Maternal and Neonatal Health Through Safer Opioid Prescribing MODULE 3

Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment

ADDICTION IN PREGNANCY

MOMS Project Panel Overview

The 14 th International Fragile X Conference, Garden Grove, CA, Friday, July 18 th, 2014

Opioids in Pregnancy. Beyond to Baby GENERAL INFO

Born on Opioids 11/15/2018. Current Epidemic of Opiates. Opioid Exposed Infant. Khalid Awad, MD

Treating Women for Substance Use Disorders and Their Children: Evidence-based Care

9/19/13. Postpartum Counseling for Women in MAT. Katie Clark MSPH, CSAC. A little about Katie. Definitions. MAT: Medication-Assisted Treatment

Inequalities in health and their effect on the newborn

Beacon Assessment Center Developmental Questionnaire Please complete prior to your first appointment

Neonatal Intensive Care Unit Clinical Guideline. Abstinence and Withdrawal in Neonates. Background

2/28/2017. Substance Use Disorders + Pregnancy. Substance Use Disorders + Pregnancy. + Prevalence of the Problem

NEONATAL ABSTINENCE SYNDROME (NAS) AKA NEWBORN DRUG WITHDRAWAL:THE NEWARK EXPERIENCE

Substance Use During Pregnancy. I have no conflicts of interest or relevant financial relationships with any commercial entities.

Neonatal Abstinence: It s No Child s Play!

4/19/2017. Neonatal Abstinence Syndrome. Disclosures. Objectives. Kara Kuhn-Riordon, MD UC Davis Medical Center. I have no financial disclosures

What To Expect. Maternal Cannabis Use during Pregnancy and the Impacts on Offspring

KRISANNA DEPPEN, MD FAMILY MEDICINE, ADDICTION MEDICINE GRANT MEDICAL CENTER-OHIOHEALTH COLUMBUS, OH

Testimony of Debra L. Bogen, MD, F AAP, F ABM

State of the Science on Pregnant and Parenting Women with Substance Use Disorder

Neonatal Abstinence Syndrome:

10/15/2018. The Tiniest Victims of the Opioid Crisis Tara Sundem, RN, NNP-BC, MS

Marijuana in the Obstetric Population

Opioid Abuse Treatment in Pregnancy

Neurodevelopmental Risk?

UNIVERSITY OF WASHINGTON

Buprenorphine & Controlled Substance Treatment Agreement

Clinical Policy: Neonatal Abstinence Syndrome Guidelines Reference Number: CP.MP.86 Effective Date: 10/13

Neonatal Abstinence Syndrome

THE OPIOID DEPENDENT MOTHER AND NEWBORN - AN UPDATE

MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER

Substance-Exposed Newborn

Neonatal Abstinence Syndrome

8/24/2015 ADDICTION AND PREGNANCY. Fear ADDICTION & PREGNANCY ADDICTION & PREGNANCY ADDICTION & PREGNANCY ADDICTION & PREGNANCY ADDICTION & PREGNANCY

Maternal Substance Abuse: Challenges & Opportunities for Perinatal Nurses Catherine H. Ivory, PhD, RNC-OB October, 2015

Opioid use in pregnancy and Neonatal Abstinence Syndrome

Neonatal Abstinence Syndrome Questions & Answers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012)

Nursing Care of the NAS Infant. Lori Markham MSN, MBA, ARNP, NNP-BC

The Impact of Neonatal Abstinence Syndrome: The View from a Rural Kentucky Hospital

ADDICTIONS. Mine Özmen, M.D. University of İstanbul Cerrahpaşa School of Medicine Department of Psychiatry

SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION

Neonatal Abstinence Syndrome: An Evidence- Based Review for the Family Nurse Practitioner

ADULT INITIAL EVALUATION: Patient Form

Johann Hari. Truths 2/29/2016. From the street to the NICU. Treatment works

Child Welfare and Substance Abuse. Erica Tarasovitch, MSW Central Florida Behavioral Health Network

Project TEACH Addressing Tobacco Treatment for Pregnant Women Jan Blalock, Ph.D.

5/15/2017. Neglect. Potpourri of Child Neglect: Drug-exposure, Failure to Thrive, Medical Care. Forms of Neglect

Opioid Addiction and Dependence in Pregnancy

8/27/2018. Katie Brooks, DO, FAAP CHI Health St. Elizabeth. I have nothing to disclose

Overdose Prevention and Intervention Task Force January 10, 2018

Transcription:

Neonatal Nursing Education Brief: The Long-Term Outcomes of Infants with Neonatal Abstinence Syndrome https://www.seattlechildrens.org/healthcareprofessionals/education/continuing-medical-nursing-education/neonatalnursing-education-briefs/ The incidence of opioid drug use in the US is increasing. The incidence of Neonatal Abstinence Syndrome is also increasing. Many infants who experience drug withdrawal require admission to the NICU and lengthy periods of treatment. The long term outcomes for these infants require ongoing support and are important to understand and address. Drug withdrawal, NAS, NICU, opioid addiction, long-term outcomes The Long-Term Outcomes of Infants with Neonatal Abstinence Syndrome Purpose and Goal: CNEP # 2094 Understand the effects of maternal opioid use on the neonate. Learn about the long-term outcomes for infants exposed to opioids. None of the planners, faculty or content specialists has any conflict of interest or will be presenting any off-label product use. This presentation has no commercial support or sponsorship, nor is it co-sponsored. Requirements for successful completion:

Successfully complete the post-test Complete the evaluation form Date November 2018 November 2020 Learning Objectives Describe the characteristics of neonatal abstinence syndrome (NAS). Describe the long-term effects of in utero opioid exposure on the neonate. Introduction The incidence of opioid use has increased Maternal opioid use has increased Illicit drug use Prescription drug use Fetal drug exposure has increased The incidence of NAS has also increased Every hour in the US, an infant is born with NAS >10,000 babies are born with NAS every year Infants with NAS may require long-term support Neonatal Abstinence Syndrome NAS is a variable and complex disorder It is seen in infants exposed to opioids in utero Heroin

Fentanyl Morphine Codeine Methadone Buprenorphine Hydromorphone It can also be seen with other substances SSRIs Nicotine Benzodiazepines NAS describes a spectrum of signs and symptoms Symptoms of behavioral disorganization State control and attention Motor and tone control Sensory integration Autonomic functioning 75-90% of exposed babies develop NAS The number of babies requiring treatment Varies between 42-94% ~27/1000 NICU admissions Median length of stay 13-19 days Clinical Manifestations of NAS The onset of NAS is widely variable The presentation can also be widely variable The variability is poorly understood This is likely due to several factors Maternal exposures Substances used Polysubstance use Psychotropic drug use Timing of exposures Frequency and dose of drugs

Maternal factors Stress Nutrition Infections Placental opioid metabolism Genetics and Epigenetics Infant factors Infections Preterm birth Metabolic rate Environmental factors Physical environment Clinical Presentation of NAS The characteristic signs of NAS include: Tremors Irritability Tachypnea High-pitched cry Sleep disturbances Hyperactive reflexes Hypertonic muscle tone Skin excoriation Feeding difficulties Gastrointestinal disturbances Vomiting Loose stools Autonomic dysfunction Sweating Sneezing Mottling Fever Nasal stuffiness Yawning

Failure to thrive Other findings in NAS include: Small for gestational age Respiratory complications Abnormal EEG changes Reported in >30% Seizure activity Reported in 2-11% Long-Term Outcomes in NAS Long-term studies are challenging Chronic stress Family instability Mistrust of healthcare Inconsistent caregiving Out-of-home placements There is evidence NAS has a long-term impact Several studies report long-term outcomes Behavioral problems are common Developmental problems are common Specific long-term problems include: Otitis media Vision problems Motor development problems Behavioral and cognitive problems Child abuse and neglect Risk of future drug use Risk of SIDS or SUID Infants raised by drug using caregivers Have poor outcomes Infants raised by non-drug using caregivers Have improved outcomes

Environmental risks magnify weaknesses caused by exposure Referral for early intervention and support is important Specific Long-Term Problems Otitis media problems Otitis media is common with methadone Severe or chronic otitis media: Hearing disabilities Developmental disabilities Learning disabilities Recurrent otitis media: Hearing loss Language delays Vision problems There is growing evidence about impairment Vision problem include: Strabismus Nystagmus Reduced acuity Refractive errors Cerebral impairment Overall visual development is delayed Motor problems There is inconsistent evidence about development Methadone exposed infants tend to develop normally Buprenorphine exposed infants tend to be delayed Significant motor skills delay Impulsivity Hyperactivity Significant memory skills delay Short attention spans

Behavioral and cognitive problems Heroin exposed infants have poor development Poor cognitive skills Poor perceptual skills Poor memory skills Methadone exposed infants have ongoing problems Hyperactivity Poor verbal skills Poor memory skills Poor perceptual skills Buprenorphine exposed infants have similar problems Hyperactivity Poor memory skills Child abuse and neglect Adverse childhood experiences can cause: Obesity Cardiovascular disease Psychiatric illnesses Genetic, social and environmental factors Complex interplay of outcomes Complex interpersonal trauma is common Lack of responsiveness to infant Unrealistic expectations of infant Increased maternal aggression Increased physical punishment Intergenerational transmission Intergenerational trauma is commonly seen Distorted thought patterns Poor parenting interactions Poor self-esteem and sense of worth Heightened sensitivity to drug triggers The incidence of child abuse is tripled With psychiatric illnesses

With drug using caregivers With environmental stressors Child Protective Services considers drug use A primary factor in child abuse A primary factor in child neglect Risk of future drug use Studies show higher rate of drug use With tobacco exposure With marijuana exposure Studies have not shown these effects with opioids Large longitudinal research studies are needed Risk of SIDS or SUID A few studies have shown an increase in SIDS All SIDS deaths reported tobacco using mothers More studies are needed before inferring an association Summary Maternal opioid use is an increasing problem More infants are being born exposed to opioids More infants are requiring hospitalization and treatment The short-term effects of NAS are well documented The long-term effects are becoming more well known Early intervention and environmental stability are important Parent education and support is crucial Ongoing intervention can optimize outcomes References Maguire, D.J., Taylor, S., Armstrong, K., Shaffer-Hudkins, E., Germain, A.M., Brookes, S.S., Cline, G.J. and Clark, L. 2016. Long-Term Outcomes of Infants with Neonatal Abstinence Syndrome. Neonatal Network, 35 (2), p. 277-286.

Vassoler, F.M., Byrnes, E.M. and Pierce, R.C. 2014. The Impact of Exposure to Addictive Drugs on Future Generations: Physiological and Behavioral Effects. Neuropharmacology, 76 (B), p. 269-275. Jansson, L.M. 2016. Neonatal Abstinence Syndrome. Up-To-Date: https://www.uptodate.com/contents/neonatal-abstinencesyndrome?source=machinelearning&search=nas%20outcomes&selectedt itle=4~13&sectionrank=1&anchor=h16#h16 Evaluation * Required fields Your information *Your name *Your email address *Your Seattle Children's ID *Your hospital Seattle Children s Hospital Providence Regional Medical Center Everett Overlake Medical Center St. Joseph Medical Center St. Francis Hospital Harrison Medical Center Other Medical Center or Hospital Test The rate of maternal opioid use has not changed in 40 years.

True False The risk of NAS is predicted by the type of in utero drug exposure. True False All infants exposed to opioids in utero will require treatment. True False Infants exposed to opioids in utero are not at risk for otitis media. True False Infants exposed to opioids in utero do not have long-term problems. True False Environmental stressors magnify the effects of in utero opioid exposure. True False Evaluation We hope you found this educational offering both interesting and informative. We d like to hear from you and appreciate you taking the time to answer these evaluation questions. *Were you able to complete this activity in the allotted time? Yes No

Were you informed of the following disclosures? *Purpose of learning activity Yes No *Requirements for successful completion of this CNE activity Yes No *Presence or absence of conflict of interest of planning committee members Yes No *Presence or absence of conflict of interest of content specialist(s)/author(s)/feedback person(s) Yes No *Were your personal objectives successfully achieved? Yes Somewhat No If not, why not? *What one thing might you do differently in your practice after this session? Please evaluate the brief:

*Presentation organized Excellent Very good Good Fair Poor *Materials offered relevant content Excellent Very good Good Fair Poor *Assistance provided as needed Excellent Very good Good Fair Poor Not applicable *Overall strength of presentation Excellent Very good Good Fair Poor Stated objectives achieved? *Describe the characteristics of neonatal abstinence syndrome.

Excellent Very good Good Fair Poor *Describe the long-term outcomes for neonates exposed to opioids. Excellent Very good Good Fair Poor